In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perlegen Sciences Inc.

www.perlegen.com

Latest From Perlegen Sciences Inc.

Remicade props up Mitsubishi Tanabe

Net pharmaceutical sales at Mitsubishi Tanabe Pharma(MTP) in Japan slipped by 1% to ¥191.0 billion ($1.97 billion) in the first half to September 30th, hit by the general April price cut and pre-merger stocking by wholesalers in the previous year.

Metabolic Disorders Cardiovascular

Best of the Blog: Personalized Medicine vs. Comparative Effectiveness

Readers of The IN VIVO Blog and The RPM Report's First Take responded to a post on whether proponents of personalized medicine can also be supporters of comparative effectiveness research. We asked readers to weigh in on that question. Their emails initiated a lively discussion on the future of health care so we've picked excerpts from the most noteworthy responses to share.
BioPharmaceutical Platform Technologies

Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q4 2007

Highlights from the Q4 2007 review of medical device and in vitro diagnostics/research dealmaking: there was a boost in medical device acquisitions--with patient monitoring in particular, which accounted for about half the total of this period--capping off an impressive year in medtech M&A activity. Of note in the in vitro diagnostics/research space was glucose monitoring, which brought in 60% of the total GM segment's $160 million in financing for the entire year.
BioPharmaceutical Medical Device

Deals Update

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Perlegen Sciences Inc.
  • Senior Management
  • Bryan Walser, MD, CEO
    Joseph Lehnen, CFO
    David R Cox, MD, PhD, CSO
    Kevin D Cooksy, VP, Bus. Dev.
    Mark J Ostrowski, SVP, Sales
  • Contact Info
  • Perlegen Sciences Inc.
    Phone: (650) 625-4500
    2021 Stierlin Ct.
    Mountain View, CA 94943
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register